Chugai Pharmaceutical Co., Ltd.
4519.T · JPX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 1.57 | -2.06 | 0.63 | 0.49 |
| FCF Yield | 3.44% | 3.82% | 3.12% | 3.37% |
| EV / EBITDA | 19.12 | 17.54 | 9.48 | 13.08 |
| Quality | ||||
| ROIC | 20.16% | 18.46% | 25.91% | 25.73% |
| Gross Margin | 70.97% | 62.36% | 62.15% | 66.04% |
| Cash Conversion Ratio | 1.16 | 1.26 | 0.42 | 0.59 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.42% | 3.59% | 16.99% | 99,991,832.68% |
| Free Cash Flow Growth | 18.18% | 94.17% | -16.39% | 43.96% |
| Safety | ||||
| Net Debt / EBITDA | -0.92 | -0.94 | -0.37 | -0.56 |
| Interest Coverage | 5,725.34 | 5,069.09 | 8,899.03 | 8,851.80 |
| Efficiency | ||||
| Inventory Turnover | 1.42 | 1.53 | 1.63 | 1.63 |
| Cash Conversion Cycle | 344.71 | 296.01 | 261.87 | 250.00 |